UNASSIGNED: We performed a transcriptomic analysis of 26 PDAC samples grouped into 3 metabolic clusters (M_CL) according to their PJ metabolic profile. We analyzed molecular subtypes and transcriptional differences. Validation was performed by multidimensional imaging on tumor slides.
UNASSIGNED: Pancreatic juice metabolic profiling was associated with PDAC transcriptomic molecular subtypes (p=0.004). Tumors identified as M_CL1 exhibited a non-squamous molecular phenotype and demonstrated longer survival. Enrichment analysis revealed the upregulation of immune genes and pathways in M_CL1 samples compared to M_CL2, the group with worse prognosis, a difference confirmed by immunofluorescence on tissue slides. Enrichment analysis of 39 immune signatures by xCell confirmed decreased immune signatures in M_CL2 compared to M_CL1 and allowed a stratification of patients associated with longer survival.
UNASSIGNED: PJ metabolic fingerprints reflect PDAC molecular subtypes and the immune microenvironment, confirming PJ as a promising source of biomarkers for personalized therapy.
■我们对26个PDAC样品进行了转录组学分析,根据其PJ代谢谱分为3个代谢簇(M_CL)。我们分析了分子亚型和转录差异。通过对肿瘤载玻片的多维成像进行验证。
■胰液代谢谱与PDAC转录组分子亚型相关(p=0.004)。被鉴定为M_CL1的肿瘤表现出非鳞状分子表型并显示出更长的生存期。富集分析显示,与预后较差的M_CL2相比,M_CL1样本中的免疫基因和途径上调,通过组织载玻片上的免疫荧光证实的差异。通过xCell的39个免疫特征的富集分析证实了与M_CL1相比M_CL2中的免疫特征降低,并且允许与更长存活相关的患者的分层。
■PJ代谢指纹图谱反映了PDAC分子亚型和免疫微环境,确认PJ是个性化治疗的有希望的生物标志物来源。